SPDR S&P US Health Care Select Sect ETF(SSEHF.US)

AbbVie plans to build out its presence in obesity market

AbbVie is expanding its presence in the obesity treatment market by leveraging Gubra's weight-loss drug, GUBamy, which mimics the hormone amylin. This drug aims to provide an alternative to GLP-1 drugs like Wegovy and Zepbound, focusing on better tolerability and durability of weight loss. AbbVie believes its existing aesthetics business positions it well, as patients seeking cosmetic treatments are also interested in weight loss solutions. The obesity drug market is projected to reach $150 billion in annual sales within the next decade.

UnitedHealthcare to Support Rural Hospitals with Accelerated Medicare Advantage Payments, Providing Immediate Cash-Flow Relief

UnitedHealthcare has launched the Rural Payment Acceleration Pilot to support independent rural hospitals by accelerating Medicare Advantage payment timelines from less than 30 days to under 15 days. This initiative aims to provide immediate cash-flow relief and enhance the sustainability of these hospitals. CEO Bobby Hunter emphasized the importance of rural hospitals in communities and the goal of improving patient care. The pilot will inform future expansions to additional hospitals, reinforcing UnitedHealthcare's commitment to rural health stability.

Intuitive Surgical | 8-K: FY2025 Q4 Revenue Beats Estimate at USD 2.87 B

Intuitive Surgical Reports 21% Revenue Growth for 2025

Intuitive Surgical Inc. reported a 21% revenue growth for 2025, with preliminary full-year revenue reaching approximately $10.06 billion. The fourth quarter revenue was about $2.87 billion, a 19% increase from the previous year. Worldwide procedures using the da Vinci and Ion platforms grew by 18%, with da Vinci procedures up 17% and Ion procedures up 44%. The company placed 1,721 da Vinci systems in 2025, including 870 da Vinci 5 systems. A conference call to discuss full financial results is scheduled for January 22, 2026.

At the "Medical Spring Festival," NVIDIA elaborated on "How to Implement AI in Healthcare"

JP Morgan stated that NVIDIA is making a "full-stack" layout in AI healthcare, building a closed loop from chips to tools to domain models, known as the "dry lab - wet lab" flywheel. At the same time, AI is transitioning from "pilot" to "employed," with the deployment speed of commercial AI in the U.S. healthcare industry being three times that of the overall economy. At the physical laboratory level, NVIDIA is collaborating with Thermo Fisher Scientific, and the industrialization process of drug discovery is also accelerating